e-learning
resources
Munich 2006
Sunday 03.09.2006
Screening, diagnosis, staging, prognosis, biological features
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
CA-125 index and non small cell lung cancer: case report
A. Tafur, I. Cherrez-Ojeda, R. Mantilla, T. Guerrero, I. Mendoza, O. Arroba, G. Jordan (Guayaquil, Ecuador)
Source:
Annual Congress 2006 - Screening, diagnosis, staging, prognosis, biological features
Session:
Screening, diagnosis, staging, prognosis, biological features
Session type:
E-Posters in free access
Number:
595
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Tafur, I. Cherrez-Ojeda, R. Mantilla, T. Guerrero, I. Mendoza, O. Arroba, G. Jordan (Guayaquil, Ecuador). CA-125 index and non small cell lung cancer: case report. Eur Respir J 2006; 28: Suppl. 50, 595
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Non small cell lung cancer: options and outcome of treatment beyond second line
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Are there potential characteristical markers in bronquial fluid for diagnosis of small cell lung cancer (SCLC)?
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Leukemoid reaction in large cell lung cancer a case report
Source: Eur Respir J 2002; 20: Suppl. 38, 268s
Year: 2002
Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC)
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Validation and comparison of several published prognostic systems for patients with small cell lung cancer
Source: Eur Respir J 2011; 38: 657-663
Year: 2011
COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis
Source: Annual Congress 2005 - Prognostic factors in lung cancer
Year: 2005
First report of a very rare complication in a case of nonsmall cell lung carcinoma
Source: Breathe, 17 (4) 210107; 10.1183/20734735.0107-2021
Year: 2021
Small cell lung cancer in patients with elderly
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
Prognostic value of mean platelet volume in non-small cell lung cancer: a real-world, registry-based study
Source: International Congress 2019 – Early detection, follow-up and epidemiology of lung cancer
Year: 2019
The importance of Ki-67 proliferation index in small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma
Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma
Year: 2006
Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer?
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008
Advanced non small cell lung cancer: an approach fit for the twenties
Source: Virtual Congress 2020 – Lung cancer grand round
Year: 2020
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Source: Eur Respir J 2010; 35: 202-215
Year: 2010
Giant non small cell lung cancer – diagnosis and treatment
Source: Annual Congress 2008 - Congenital lung lesions and emphysema; lung cancer surgery
Year: 2008
Composite anatomical–clinical–molecular prognostic model in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 136-142
Year: 2011
Lung cancer: does age affect treatment strategy?
Source: Eur Respir Mon; 2009: 43:306–326
Year: 2009
Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s
Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement
Year: 2018
Should there be a specific management for large cell neuroendocrine carcinoma?
Source: Annual Congress 2005 - Neuroendocrine tumours of the lung
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept